Slide 1: Noninvasive Accurate Lung Cancer Detection
e e f fj ° t Noninvasive Accurate Lung Cancer Detection /\ | a) | Re 7 ia with proprietary TECHNOLOGIES cytometry data SPRING 2026 INVESTOR PRESENTATION
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation and statements by management or other Persons acting by or on behalf of bioAffinity Technologies made in connection With this presentation constitute “forward-looking statements” within the meaning of the sa
Slide 3: Lung Cancer Is A Global Problem and Large Market
Lung Cancer Is A Global Problem and Large Market Leading cause of cancer-related deaths 2.48 Million 1.8 Million New cases worldwide annually! Deaths annually! An estimated 19.3 million Americans should have annual lung cancer screening according to the American Cancer Society? | e Major Screening N
Slide 4: Slide
Slide 3 MZ1 Lung cancer is not the most common caner. Skin cancers, and then breast cancer is more commonly diagnosed. Maria Zennes, 2026.
Slide 5: Early Detection of Lung Cancer Saves Lives
Early Detection of Lung Cancer Saves Lives Improving survival rates through timely intervention and accurate diagnosis Current Survival Rates © In 2025, less than 30% of patients survived 5 years? Late-Stage Diagnosis Most patients are diagnosed with late-stage cancer (Stages Ill-IV) when survival r
Slide 6: CyPath Lung Platform
CyPath Lung Platform Detecting Lung Cancer with Noninvasive Technology 92%* 87%* 99%* 88%* Sensitivity! Specificity’ NPV! Accuracy! & a = Proprietary Al Analysis Patient-Friendly & Physician-Focused Growing Platform Technology v Aldriven algorithm analyzes complex flow vy At-home collection (no need
Slide 7: CyPath Lung in Action: Patient Case Studies
CyPath Lung in Action: Patient Case Studies* Demonstrating Detection at Curative Stage 1A & Averting Risky Procedures bioAffinity TECHNOLOGIES 8 LIKELY MALIGNANCY (a) "Gloria" “Paula” | Usuken Maticnancr LIKELY MALIGNANCY fo] "James" Challenge: PET scan and serum markers Challenge: Bronchoscopy and
Slide 8: CyPath Lung in Action: Patient Case Studies
CyPath Lung in Action: Patient Case Studies* Case Studies Demonstrate Cancer Detection In Surveillance Period; Earlier Detection of Malignant Ground Glass Nodule e LIKELY MALIGNANCY “Joan” Challenge: Surveillance in high-risk survivors is challenging. CyPath® Result: Returned a "likely" result durin
Slide 9: Compares Favorably to Standards of Care
Compares Favorably to Standards of Care Proven Clinical Utility To Help Detect Lung Cancer Noninvasively %& CyPath® Lung! Fine Needle Biopsy* Core Needle Biopsy* FDG PET imaging? Bronchoscopy? £06 = fuorodeoryglucose; PET positron emision tomography 4.M.Lemievr, etl, Detection of eal stage cancer in
Slide 10: Physician-Focused, Patient-Friendly, Reimbursed by Insurance
Physician-Focused, Patient-Friendly, Reimbursed by Insurance ra a we @ Clinic @ Home @ Laboratory @ Clinic Physician orders CyPath® Patient videos, written Al-driven automated Physician receives results Lung test to ship to patient instructions and personal analysis of flow cytometry within 3 days a
Slide 11: Interpreting the Report
Interpreting the Report CyPath Lung jb ABORATORY Seale reflects cancer probability Reference Ranges 20.00 & <0.50 Unlikely 20.50 & < 1.00 Likely JAW Patient: DOE, JANE Collection Date: 01/08/2026 recision Pathology Laboratory Services - Nacogdoches DOB | Age / Sex: 01/06/1955 , 71, Received Date: 01
Slide 12: Significant Healthcare Savings
Significant Healthcare Savings Economic Impact Analysis 2024 study’ authored by pulmonologists practicing at Audie L. Murphy Memorial VA Hospital and Brooke Army Medical Center evaluated CyPath’ Lung’s potential economic impact if added to the standard of care. Medicare Patient Commercial Insurance
Slide 13: How the Test Works
How the Test Works Flow Cytometry Interrogates Lung Microenvironment ‘Sputum samples are processed into a single-cell suspension and labelled before data acquisition with antibodies, reagents, labeling agents and TCPP. Proprietary Al-Driven Platform Analysis Automated analysis identifies cell popula
Slide 14: Market Opportunity
Market Opportunity The U.S. market for CyPath Eung ist) poised for significant growths \8/ — fh if i, es 2030 Market Opportunity Indeterminate Pulmonary Nodules . 2025 ad 2030 The total number of indeterminate pulmonary nodules At 10% Market Share 4 (IPNs) detected by lung cancer screening and incid
Slide 15: Market Opportunity
Market Opportunity CyPath® Lung Use for Surveillance of Lung Cancer Recurrence 2030 Market Opportunity $87 MM @ At 10% Market Share y Lung Cancer Survivors 680,450 <A” 2025 +28% 2035 The total number of people living with lung cancer is projected to increase by 28% from 680,450 survivors in 2025 to
Slide 16: Revenue & Key Business Milestones Achieved in 2025
Revenue & Key Business Milestones Achieved in 2025 Jan ‘25 Le) 99% Year-over-year increase in CyPath® Lung units sold 87% Year-over-year increase in revenue Published multiple case studies and physician testimonials A Solid Foundation for Growth Es Entered major VA medical centers with lung nodule p
Slide 17: Longitudinal Clinical Trial Launches in 2026
Longitudinal Clinical Trial Launches in 2026 EA 2,000 ~20 Q1 2026 Patients Collection Sites Enrollment Underway Designed to assess CyPath® Lung performance for risk stratification, clinical decision-making, detection and survivor surveillance. John P. Murtha Cancer ready) with funding and support fr
Slide 18: Building on a Successful Diagnostic Platform
Building on a Successful Diagnostic Platform Next in Pipeline: Companion Diagnostics for Asthma and COPD Quantifying Lung Inflammation for Improved Therapy Precision Diagnostics Match patients to effective 23M 27M treatments and monitor their effectiveness over time, Adults in the US. People in the
Slide 19: Management
Management Innovative, Experienced, Dedicated | Executive Leadership a & (4 Maria Zanes, JD Gordon Downie, MD, PhD Michael Edwards, MBA William Bauta, PhD Xavier Reveles, MS Founder, CEO & President Chief Medical Officer Chief Financial Officer Chief Science Officer Chief Operating Officer aneyears
Slide 20: Board of Directors
Board of Directors Decades of Successful Leadership from Start-Ups to Global Corporations Steve Girgenti 2 Executive Chairman Founded leading global healthcare ‘marketing firm Healthweorld with 32, offices worldwide, Recegnized as NASDAQ’s 1999 "Entrepreneur of the Roby Joyce, MD Director Precision
Slide 21: Maria Zannes
Maria Zannes President & CEO mz@bioaffinitytech.com & 505-400-9747 bidAffinity bioAfinity Technolegies (Nescer: BUAF)|